(Q44398270)

English

Development and preclinical safety evaluation of a new therapeutic HIV-1 vaccine based on 18 T-cell minimal epitope peptides applying a novel cationic adjuvant CAF01.

scientific article published on 19 July 2011

In more languages

Statements

scholarly article

1 reference

Europe PubMed Central

2 December 2017

Development and preclinical safety evaluation of a new therapeutic HIV-1 vaccine based on 18 T-cell minimal epitope peptides applying a novel cationic adjuvant CAF01. (English)

1 reference

Europe PubMed Central

2 December 2017

Anders Fomsgaard

object named as

Anders Fomsgaard

1

0 references

object named as

Peter Andersen

8

0 references

author name string

Ingrid Karlsson

2

1 reference

Europe PubMed Central

2 December 2017

Gregers Gram

3

1 reference

Europe PubMed Central

2 December 2017

Christian Schou

4

1 reference

Europe PubMed Central

2 December 2017

Sheila Tang

5

1 reference

Europe PubMed Central

2 December 2017

Peter Bang

6

1 reference

Europe PubMed Central

2 December 2017

Ingrid Kromann

7

1 reference

Europe PubMed Central

2 December 2017

Lars Vibe Andreasen

9

1 reference

Europe PubMed Central

2 December 2017

language of work or name

0 references

publication date

19 July 2011

1 reference

Europe PubMed Central

2 December 2017

1 reference

Europe PubMed Central

2 December 2017

29

1 reference

Europe PubMed Central

2 December 2017

40

1 reference

Europe PubMed Central

2 December 2017

7067-7074

1 reference

Europe PubMed Central

2 December 2017

The immune response during acute HIV-1 infection: clues for vaccine development

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2011.07.025

7 January 2021

Dose-response curve slope sets class-specific limits on inhibitory potential of anti-HIV drugs

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2011.07.025

7 January 2021

Are we on course for reporting on the Millennium Development Goals in 2015?

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2011.07.025

7 January 2021

Therapeutic vaccines for chronic infections

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2011.07.025

7 January 2021

Therapeutic dendritic-cell vaccine for chronic HIV-1 infection

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2011.07.025

7 January 2021

Optimization and immune recognition of multiple novel conserved HLA-A2, human immunodeficiency virus type 1-specific CTL epitopes

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2011.07.025

7 January 2021

Sequence conservation of subdominant HLA-A2-binding CTL epitopes in HIV-1 clinical isolates and CD8+ T-lymphocyte cross-recognition may explain the immune reaction in infected individuals

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2011.07.025

7 January 2021

Induction of novel CD8+ T-cell responses during chronic untreated HIV-1 infection by immunization with subdominant cytotoxic T-lymphocyte epitopes

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2011.07.025

7 January 2021

Cationic liposomes formulated with synthetic mycobacterial cordfactor (CAF01): a versatile adjuvant for vaccines with different immunological requirements

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2011.07.025

7 January 2021

A comparative study of cationic liposome and niosome-based adjuvant systems for protein subunit vaccines: characterisation, environmental scanning electron microscopy and immunisation studies in mice

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2011.07.025

7 January 2021

Characterization of cationic liposomes based on dimethyldioctadecylammonium and synthetic cord factor from M. tuberculosis (trehalose 6,6'-dibehenate)-a novel adjuvant inducing both strong CMI and antibody responses

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2011.07.025

7 January 2021

The adjuvant mechanism of cationic dimethyldioctadecylammonium liposomes

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2011.07.025

7 January 2021

Cationic liposomes as vaccine adjuvants

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2011.07.025

7 January 2021

A novel liposome-based adjuvant CAF01 for induction of CD8(+) cytotoxic T-lymphocytes (CTL) to HIV-1 minimal CTL peptides in HLA-A*0201 transgenic mice

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2011.07.025

7 January 2021

Liposome-based cationic adjuvant formulations (CAF): past, present, and future

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2011.07.025

7 January 2021

Broadly immunogenic HLA class I supertype-restricted elite CTL epitopes recognized in a diverse population infected with different HIV-1 subtypes.

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2011.07.025

7 January 2021

Early induction and maintenance of Env-specific T-helper cells following human immunodeficiency virus type 1 infection

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2011.07.025

7 January 2021

Identification and antigenicity of broadly cross-reactive and conserved human immunodeficiency virus type 1-derived helper T-lymphocyte epitopes.

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2011.07.025

7 January 2021

Development of experimental carbohydrate-conjugate vaccines composed of Streptococcus pneumoniae capsular polysaccharides and the universal helper T-lymphocyte epitope (PADRE).

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2011.07.025

7 January 2021

The role of CD4(+) T helper cells in the cytotoxic T lymphocyte response to HIV-1.

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2011.07.025

7 January 2021

CD4+ T cells support cytotoxic T lymphocyte priming by controlling lymph node input.

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2011.07.025

7 January 2021

HLA class I supertypes: a revised and updated classification

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2011.07.025

7 January 2021

Phase I therapeutic trial of the HIV-1 Tat protein and long term follow-up.

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2011.07.025

7 January 2021

Therapeutic immunization with HIV-1 Tat reduces immune activation and loss of regulatory T-cells and improves immune function in subjects on HAART

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2011.07.025

7 January 2021

Immunogenicity and safety of a novel therapeutic hepatitis C virus (HCV) peptide vaccine: a randomized, placebo controlled trial for dose optimization in 128 healthy subjects.

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2011.07.025

7 January 2021

A mouse model of human adaptive immune functions: HLA-A2.1-/HLA-DR1-transgenic H-2 class I-/class II-knockout mice

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2011.07.025

7 January 2021

Response definition criteria for ELISPOT assays revisited

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2011.07.025

7 January 2021

The utility of the minipig as an animal model in regulatory toxicology

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2011.07.025

7 January 2021

HLA-A2.1-restricted education and cytolytic activity of CD8(+) T lymphocytes from beta2 microglobulin (beta2m) HLA-A2.1 monochain transgenic H-2Db beta2m double knockout mice

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2011.07.025

7 January 2021

Development of a HIV-1 lipopeptide antigen pulsed therapeutic dendritic cell vaccine

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2011.07.025

7 January 2021

Control of viremia and prevention of AIDS following immunotherapy of SIV-infected macaques with peptide-pulsed blood

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2011.07.025

7 January 2021

Processing and presentation of exogenous HLA class I peptides by dendritic cells from human immunodeficiency virus type 1-infected persons

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2011.07.025

7 January 2021

Cross-reactive CD8+ T cell epitopes identified in US adolescent minorities

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2011.07.025

7 January 2021

An HLA-A11-specific motif in nonamer peptides derived from viral and cellular proteins

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2011.07.025

7 January 2021

Identifiers

10.1016/J.VACCINE.2011.07.025

1 reference

Europe PubMed Central

2 December 2017

1 reference

Europe PubMed Central

2 December 2017

Sitelinks

Wikipedia(0 entries)

Wikibooks(0 entries)

Wikinews(0 entries)

Wikiquote(0 entries)

Wikisource(0 entries)

Wikiversity(0 entries)

Wikivoyage(0 entries)

Wiktionary(0 entries)

Multilingual sites(0 entries)

Retrieved from "https://www.wikidata.org/w/index.php?title=Q44398270&oldid=1369008360"